Düsseldorf, April 14, 2011 – At its Annual General Meeting today Gerresheimer AG looked back at the very good financial year 2010. The shareholders passed a resolution approving payment of a dividend of EUR 0.50 per share.
At the meeting of shareholders in Düsseldorf the CEO Uwe Röhrhoff summarized the year as follows: “The financial year 2010 went very successfully for us. Our products and services are very popular with our international pharma customers. We achieved our targets and actually exceeded some of them. We wish to allow our shareholders to participate in this success.”
“In the coming years we see further major growth opportunities, particularly in the emerging countries. We want to become the leading global partner for solutions which contribute to improvements in health and well-being,” Röhrhoff added.
The dividend of EUR 0.50 per share is to be paid on April 15, 2011. The dividend distribution is basically tax-free for shareholders based in Germany. No dividend was paid in the prior year.
With capital stock representation of 68.27 percent the General Meeting passed the following resolutions on agenda items:
ITEM 2: Appropriation of net earnings for the financial year 2010: Votes in favor 99.99 percent
ITEM 3: Formal approval of the actions of the members of the Management Board for the financial year 2010: Votes in favor 96.34 percent
ITEM 4: Formal approval of the actions of the members of the Supervisory Board for the financial year 2010: Votes in favor 98.52 percent
ITEM 5: Election of the auditor for the financial year 2011: Votes in favor 99.69 percent
The speech to the General Meeting can be found under www.gerresheimer.com/investor-relations/hauptversammlung About Gerresheimer
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.
Our Group realizes revenues of around one billion Euros and has 10,000 employees at 45 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.
At the meeting of shareholders in Düsseldorf the CEO Uwe Röhrhoff summarized the year as follows: “The financial year 2010 went very successfully for us. Our products and services are very popular with our international pharma customers. We achieved our targets and actually exceeded some of them. We wish to allow our shareholders to participate in this success.”
“In the coming years we see further major growth opportunities, particularly in the emerging countries. We want to become the leading global partner for solutions which contribute to improvements in health and well-being,” Röhrhoff added.
The dividend of EUR 0.50 per share is to be paid on April 15, 2011. The dividend distribution is basically tax-free for shareholders based in Germany. No dividend was paid in the prior year.
With capital stock representation of 68.27 percent the General Meeting passed the following resolutions on agenda items:
ITEM 2: Appropriation of net earnings for the financial year 2010: Votes in favor 99.99 percent
ITEM 3: Formal approval of the actions of the members of the Management Board for the financial year 2010: Votes in favor 96.34 percent
ITEM 4: Formal approval of the actions of the members of the Supervisory Board for the financial year 2010: Votes in favor 98.52 percent
ITEM 5: Election of the auditor for the financial year 2011: Votes in favor 99.69 percent
The speech to the General Meeting can be found under www.gerresheimer.com/investor-relations/hauptversammlung About Gerresheimer
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.
Our Group realizes revenues of around one billion Euros and has 10,000 employees at 45 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.
You are not logged in, please sign in to view contact
Info release
Promotion
Building shop
Online business
